BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly’s tirzepatide for the treatment of obesity.
The drug developer decided to stop the trial after liver transaminitis, or high levels of certain liver enzymes, were observed in patients receiving the experimental drug, azelaprag.
Tirzepatide is the active ingredient in Lilly’s diabetes drug Mounjaro and weight-loss treatment Zepbound.
The mid-stage trial enrolled about 220 individuals with obesity aged 55 years and older.
BioAge discontinues mid-stage trial of obesity drug
Date:
More like thisRelated
‘No deals for release’: Pakistan’s ex-PM Imran Khan to be released from jail? What his party leaders said
File photo of Imran Khan (Pic credit: PTI)...
Salmonella outbreak in the US: Egg recall expands; 7 states hit—here’s how to avoid getting sick
A Salmonella Enteritidis outbreak linked to cage-free and...
Supreme Court orders ex-husband to transfer house, pay Rs 50,000 monthly alimony to divorced wife, with biennial hike | India News
NEW DELHI: In a significant ruling that...
Jamie Lever opens up on facing colourism, fat-shaming; recalls being called ‘too ugly for the industry’: ‘Was told kaali hai, chudail lagti hai, that...
Actor and comedian Jamie Lever, daughter of...